# Quadruple Oral Combination Therapy for Type 2 Diabetes Mellitus : Glycemic Control by Thiazolidinedione (TZD) or Sodium Glucose Co-transporter 2 (SGLT-2) Inhibitor as an add-on Therapy in Type 2 Diabetes Mellitus After Failure of an Oral Triple Antidiabetic Regimen

> **NCT04013581** · PHASE4 · COMPLETED · sponsor: **Yonsei University** · enrollment: 121 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** TZD group
- **DRUG:** SGLT-2 group

## Key facts

- **NCT ID:** NCT04013581
- **Lead sponsor:** Yonsei University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-08-05
- **Primary completion:** 2020-05-13
- **Final completion:** 2020-05-28
- **Target enrollment:** 121 (ACTUAL)
- **Last updated:** 2021-05-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04013581

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04013581, "Quadruple Oral Combination Therapy for Type 2 Diabetes Mellitus : Glycemic Control by Thiazolidinedione (TZD) or Sodium Glucose Co-transporter 2 (SGLT-2) Inhibitor as an add-on Therapy in Type 2 Diabetes Mellitus After Failure of an Oral Triple Antidiabetic Regimen". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT04013581. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*